The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LAZCLUZE Janssen-Cilag Pty Ltd
Product name
LAZCLUZE
Sponsor
Accepted date
Apr-2024
Active ingredients
lazertinib mesilate monohydrate
Proposed indication
For the treatment of non-small cell lung cancer (NSCLC).
Application type
A (new medicine)
Publication date
Apr-2024